Rethinking Demethylating Agents in Epigenetic Cancer Therapy
Received Date: Jun 08, 2016 / Accepted Date: Jun 23, 2016 / Published Date: Jun 27, 2016
Abstract
DNA methylation inhibitors 5-Azacytidine and 5-Aza-2’-deoxycytidine have been increasingly used in the clinic to treat myeloid disorders and cancer since their FDA approval over a decade ago. Increasing the efficiency and efficacy of these drugs require better understanding on their mechanism of action. Recent studies show that DNA methylation inhibitors have widespread anti-tumor functions and act by modulating oncogenes and tumor suppressor genes expression as well as stimulating the immune system. These findings demonstrate the significant progress that has been made in the field of epigenetic therapy to improve patients’ outcome.
Keywords: DNA methylation; Epigenetic theraphy; Oncogenes
Citation: Lay FD, Liang G (2016) Rethinking Demethylating Agents in Epigenetic Cancer Therapy. J Mol Pharm Org Process Res 4: 133. Doi: 10.4172/2329-9053.1000133
Copyright: ©2016 Lay FD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 13281
- [From(publication date): 6-2016 - Dec 19, 2024]
- Breakdown by view type
- HTML page views: 12482
- PDF downloads: 799
